Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/1/2020
SIETES contiene 92881 citas

 
 
<< anterior 21 a 40 de 381 siguiente >>
Presentar resultados
Seleccionar todas
21.Enlace a cita original
Brewer L, Bennett K, McGreevy C, Williams D. A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol 2013;69:1467-75. [Ref.ID 95853]
23. Cita con resumen
Kuehn BM. Challenge to Alzheimer drug. JAMA 2012;308:2557. [Ref.ID 94277]
24. Cita con resumen
Webster PC. Canada clamps down on access to drug safety data. Lancet 2012;380:1805-6. [Ref.ID 94120]
25. Cita con resumen
Rodda J, Carter J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ 2012;344:43-7. [Ref.ID 92853]
26.
27.Tiene citas relacionadas Cita con resumen
Pariente A, Fourrier-Réglat A, Ducruet T, Farrington P, Béland S-G, Dartigues J-F, Moore N, Moride Y. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med 2012;172:648-53. [Ref.ID 92791]
29. Cita con resumen
Schwartz LM, Woloshin S. How the FDA forgot the evidence: donepezil 23 mg. BMJ 2012;344:40-1. [Ref.ID 92650]
30. Cita con resumen
Anónimo. Donepezil - SSRI and SNRI - interactions and serotonin syndrome. WHO Pharmaceuticals Newsletter 2012;2:abril. [Ref.ID 92615]
31. Cita con resumen
Schwartz LM, Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ 2012;344:e1086. [Ref.ID 92531]
32.Tiene citas relacionadas
Schneider LS. Discontinuing donepezil or starting memantine for Alzheimer's disease. N Engl J Med 2012;366:957-9. [Ref.ID 92495]
33.Tiene citas relacionadas Cita con resumen
Howard RH, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes CBC, Hughes A, Jacoby R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366:914-24. [Ref.ID 92492]
34. Cita con resumen
Boudreau DM, Yu O, Gray SL, Raebel MA, Johnson J, Larson EB. Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. J Am Geriatr Soc 2011;59:2069-76. [Ref.ID 91576]
35. Cita con resumen
Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc 2011;59:1019-31. [Ref.ID 90768]
36.
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377:1019-31. [Ref.ID 90421]
37. Cita con resumen
Anónimo. NICE recommends Alzheimer's drugs for mild disease. BMJ 2011;342:678. [Ref.ID 90340]
38.Tiene citas relacionadas
van Eijk MM, van Gool W, Slooter AJC. Cholinesterase inhibitor treatment in patients with delirium. Authors' reply. Lancet 2011;377:901. [Ref.ID 90324]
39.Tiene citas relacionadas
Opdam FL, Oleksik AM, Westendorp RGJ. Cholinesterase inhibitor treatment in patients with delirium. Lancet 2011;377:900-1. [Ref.ID 90323]
40.Tiene citas relacionadas
Berg RMG, Moller K. Cholinesterase inhibitor treatment in patients with delirium. Lancet 2011;377:900. [Ref.ID 90322]
Seleccionar todas
 
<< anterior 21 a 40 de 381 siguiente >>